Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT03113422 |
Title | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403) |
Acronym | PrE0403 |
Recruitment | Completed |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | PrECOG, LLC. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | United States | Details | |
Sidney Kimmel Comprehensive Cancer Center at John Hopkins | Baltimore | Maryland | 21205 | United States | Details | |
Mayo Clinic | Rochester | Minnesota | 55905 | United States | Details | |
Washington University School of Medicine | Saint Louis | Missouri | 63110 | United States | Details | |
Rutgers Cancer Institute of NJ | New Brunswick | New Jersey | 08903 | United States | Details | |
Fox Chase | Philadelphia | Pennsylvania | 19111 | United States | Details | |
Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | United States | Details | |
University of Virginia | Charlottesville | Virginia | 22908 | United States | Details | |
Gunderson Health System Cancer Center | La Crosse | Wisconsin | 54601 | United States | Details | |
University of Wisconsin | Madison | Wisconsin | 53792 | United States | Details |